MetLife Investment Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

MetLife Investment Management’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,585	Closed	-$97.4K	–	3007
2023 Q1	$97.4K	Hold	15,585	–	–	﹤0.01%	2564
2022 Q4	$95.1K	Hold	15,585	–	–	﹤0.01%	2614
2022 Q3	$186K	Hold	15,585	–	–	﹤0.01%	2345
2022 Q2	$197K	Hold	15,585	–	–	﹤0.01%	2327
2022 Q1	$175K	Buy	15,585 +5,658	+57%	+$62.3K	﹤0.01%	2434
2021 Q4	$176K	Hold	9,927	–	–	﹤0.01%	2134
2021 Q3	$229K	Buy	+9,927	New	+$216K	﹤0.01%	2006
2021 Q2	–	Sell	-6,421	Closed	-$200K	–	2502
2021 Q1	$200K	Buy	+6,421	New	+$224K	﹤0.01%	2051

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MetLife Investment Management's KNTE Position: Q2 2023 in Review

MetLife Investment Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 15,585 shares — an estimated $97.4K sold.

MetLife Investment Management first reported a position in KNTE in Q1 2021 and held it in 8 quarters. The position peaked at $229K in Q3 2021. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

MetLife Investment Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
MetLife Investment Management sold 15,585 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $97.4K.
MetLife Investment Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 8 quarters.
MetLife Investment Management's Kinnate Biopharma Inc. Common Stock position peaked at $229K in Q3 2021.
72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on MetLife Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.